Company Quick10K Filing
Endonovo Therapeutics
10-Q 2020-06-30 Filed 2020-08-19
S-1 2020-06-23 Public Filing
10-Q 2020-03-31 Filed 2020-06-12
10-K 2019-12-31 Filed 2020-05-04
10-Q 2019-09-30 Filed 2019-11-19
10-Q 2019-06-30 Filed 2019-08-13
10-Q 2019-03-31 Filed 2019-05-09
S-1 2019-01-07 Public Filing
10-K 2018-12-31 Filed 2019-04-15
10-Q 2018-09-30 Filed 2018-11-13
10-Q 2018-06-30 Filed 2018-08-13
10-Q 2018-03-31 Filed 2018-05-18
10-K 2017-12-31 Filed 2018-04-06
10-Q 2017-09-30 Filed 2017-11-07
10-Q 2017-06-30 Filed 2017-08-10
10-Q 2017-03-31 Filed 2017-05-12
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-12
10-Q 2016-03-31 Filed 2016-05-20
10-K 2015-12-31 Filed 2016-04-05
10-Q 2015-09-30 Filed 2015-11-23
10-Q 2015-06-30 Filed 2015-08-19
10-Q 2015-03-31 Filed 2015-05-19
10-K 2014-12-31 Filed 2015-04-03
10-Q 2014-09-30 Filed 2014-11-14
10-Q 2014-06-30 Filed 2014-08-19
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-04-15
10-Q 2013-09-30 Filed 2013-12-18
10-Q 2013-06-30 Filed 2013-08-19
10-Q 2013-03-31 Filed 2013-05-20
10-K 2012-12-31 Filed 2013-04-16
10-K 2012-12-31 Filed 2013-04-16
10-Q 2012-09-30 Filed 2012-11-29
10-Q 2012-06-30 Filed 2012-08-20
10-Q 2012-03-31 Filed 2012-05-21
10-K 2011-12-31 Filed 2012-04-13
8-K 2020-08-06 Officers, Exhibits
8-K 2020-05-20
8-K 2020-05-19
8-K 2020-04-10
8-K 2020-03-02
8-K 2020-01-29
8-K 2019-12-11
8-K 2019-06-10
8-K 2019-01-01
8-K 2018-12-06
8-K 2018-09-18
8-K 2018-08-12

Endonovo Therapeutics Financials

ENDV Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
US Stem Cell (USRM) 0 58% -0.2 -481% 656 9,770 2,763 1,598 -3,158 -2,256 378
Bravatek Solutions (BVTK) 0 73% 0.0 -158% 151 8,437 199 146 -239 -114 -2
Visium Technologies (VISM) 0 0.0 -31,116% 3 3,141 0 0 -796 -796 -3
Fiverr (FVRR)
Zenergy Brands (ZNGY) 0 17% 0.0 -171% 2,124 8,074 2,085 345 -3,635 -3,635 -6
Patriot Scientific (PTSC) 0 1.2 -41% 1,925 228 0 0 -798 -797 -986
Granite Real Estate (GRP)
Growlife (PHOT) 0 33% 0.0 -130% 4,626 9,064 6,744 2,193 -6,029 -4,695 -201
Dais Analytic (DLYT) 0 36% 0.0 -597% 414 8,700 1,055 378 -2,470 -2,184 -14
Jumia (JMIA)
Rich Pharmaceuticals (RCHA) 0 -6% 0.0 -4,521% 37 6,396 115 -7 -1,692 -2,356 -6
InMode (INMD)
View Systems (VSYM) 0 100% -0.8 -1,148% 27 1,083 1 1 -308 -272 226
Owl Rock Capital (ORCC)
Endonovo Therapeutics (ENDV) 0 73% -0.8 -301% 3,414 19,980 204 150 -10,268 -9,617 7,448
Link Motion (LKM) 0 0% 853,628 377,864 0 0 0 0 -91,397
Cerence (CRNC)
W&E Source (WESC) 0 100% 0.0 -419% 14 182 1 1 -60 -60 -3
Ford Motor Credit (FMCC) 0 0% 15.7 1% 160,883,000 146,728,000 12,691,000 0 2,313,000 7,242,000 114,027,000
Sirva (SRVA)

Balance Sheet ($'000)2011-06-302011-12-312012-03-312012-06-302012-09-302013-09-302015-06-302015-09-302015-12-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash111705211311827417995561132464909568665379585485
Accounts Receivable11127103310811
Inventory
PP&E55221517474787878787878787887878787878990
Assets114731,027988969645462761022643193582031604,6124,4714,2844,7114,2423,7664,1233,414
Accounts Payable01157199281346
Long-Term Debt433532292,2851,8783,1942,8003,2953,6407,3567,3017,4898,4138,1587,4807,5207,453
Liabilities011,7462,1042,3953,5275,4515,9917,6657,3538,7838,88113,4259,35713,34414,16313,09413,40018,79315,63415,39120,36919,980
Stockholders' Equity11472-719-1,116-1,426-3,463-5,398-5,929-7,589-7,250-8,519-8,562-13,066-9,154-13,184-9,550-8,623-9,116-14,082-11,392-11,625-16,247-16,566
Income Statement ($'000)2011-06-302011-12-312012-03-312012-06-302012-09-302013-09-302015-06-302015-09-302015-12-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue928702-000007132142456354
Cost of Revenue1000001488309
Gross Profit1-00000121734373345
R&D114445111634835
SG&A
Tax0000000000000000000000
Net Income21-431-431-393-452-558-1,281-2,840-1,454-2,219-740-7,7651,858-6,6721,769-6194,802-5,9481,382-2,406-7,838-1,406
Cash Flow ($'000)2011-06-302011-12-312012-03-312012-06-302012-09-302013-09-302015-06-302015-09-302015-12-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-20-176-33-429-211-776-659-434-914-829-813-591-742-716-528-688-1,017
Cash Investing530000000-3,000-9000-2-1
Cash Financing10135254382297926204928258823,8266057144302081,179475